Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,092 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Disease Chronic Clear all
Completed No phase listed Observational

Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs

NCT04628039
View directory record Official record
Conditions
COVID-19, Chronic Lung Diseases
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

NCT02639338
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 8, 2026, 3:20 PM EDT
Recruiting Not applicable Interventional

Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema

NCT04801108
View directory record Official record
Conditions
Emphysema or COPD
Interventions
Robotic or VATS lobar fissure completion, Endobronchial valves placement
Procedure · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Results available

A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

NCT01691482
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol/salbutamol, Ipratropium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 8, 2026, 3:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

NCT05421208
View directory record Official record
Conditions
Post-acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), Long COVID, SARS CoV 2 Infection
Interventions
Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls, Levels of inflammatory cytokine ( IL-6) in controls, Effect on inflammation after chronic PNS stimulation
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 8, 2026, 3:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

NCT04583878
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Blood draw (Visit 1), Blood draw (Visits 2 and 3)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 8, 2026, 3:20 PM EDT
Not listed No phase listed Observational

Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone

NCT05133713
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Catheter directed therapy, Systemic anticoagulation
Device · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

NCT02168686
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
ADVM-043
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 8, 2026, 3:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Birmingham, Alabama • Dothan, Alabama • Jasper, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 8, 2026, 3:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

NCT00144339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
5,993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Not applicable Interventional Results available

Modulating Interaction of Motor Learning Networks in Rehabilitation of Stroke

NCT03086551
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Stroke, Middle Cerebral Artery With Infarction
Interventions
Active continuous theta burst stimulation (cTBS), Placebo (Sham) continuous theta burst stimulation, Motor Practice
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

NCT02454959
View directory record Official record
Conditions
COPD
Interventions
GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
Device
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 2 Interventional

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

NCT00672802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 8, 2026, 3:20 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Accessing Mobility Using Wearable Sensors

NCT04306588
View directory record Official record
Conditions
COPD, Pulmonary Disease, Pulmonary Restrictive Disease, Congestive Heart Failure, Cardiovascular Diseases
Interventions
Exercise
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 8, 2026, 3:20 PM EDT
Recruiting No phase listed Observational

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

NCT05866302
View directory record Official record
Conditions
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
36 Months and older
Enrollment
375 participants
Timeline
2023 – 2028
U.S. locations
6
States / cities
Stanford, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 8, 2026, 3:20 PM EDT
Terminated Phase 4 Interventional Results available

Ventilator Adapters for Combivent Respimat

NCT01969539
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent Respimat via tee adapter, Combivent Respimat via ventilator adapter
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Danbury, Connecticut • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 8, 2026, 3:20 PM EDT
Completed No phase listed Observational

Developing Enhanced Prediction Models

NCT02983812
View directory record Official record
Conditions
Acute Myocardial Infraction or Chest Pain, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Diabetes, Pneumonia
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 8, 2026, 3:20 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 8, 2026, 3:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 8, 2026, 3:20 PM EDT
Completed Not applicable Interventional

Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)

NCT01349608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity, Health Behavior
Interventions
Telephonic health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 8, 2026, 3:20 PM EDT
Completed No phase listed Observational

Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations

NCT00281216
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 8, 2026, 3:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection

NCT05866952
View directory record Official record
Conditions
Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
Interventions
Computed Tomography of the Chest
Diagnostic Test
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 8, 2026, 3:20 PM EDT